Soligenix, Inc. (SNGX)

Market Cap	4.15M
Revenue (ttm)	2,342
Net Income (ttm)	-9.59M
Shares Out	3.26M
EPS (ttm)	-4.25
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	124,329
Open	1.270
Previous Close	1.270
Day's Range	1.238 - 1.300
52-Week Range	1.090 - 8.550
Beta	1.88
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 8, 2025

About SNGX

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflam...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 15, 1987
• Employees: 16
• Stock Exchange: NASDAQ
• Ticker Symbol: SNGX
• Website: https://www.soligenix.com

Financial Performance

In 2024, Soligenix's revenue was $119,371, a decrease of -85.78% compared to the previous year's $839,359. Losses were -$8.27 million, 34.6% more than in 2023.